At the ASCO 2019 annual meeting, trial investigator, Kazuhiko Nakagawa discusses RELAY: A multinational, double-blind, randomized Phase III study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NCT02411448).
1. What is the rationale for the use of ramucirumab plus erlotinib in metastatic EGFR-mutated non-small cell lung cancer (NSCLC)? (0:03)
2. Could you tell us a little about the RELAY study and its findings? (0:48)
3. What was the safety profile of ramucirumab plus erlotinib? (1:43)
4. Which patients are most likely to respond to this therapy? (2:49)
5. Following the success of the RELAY and REVEL studies, what will be the next steps in the clinical development of ramucirumab in NSCLC? (3:55)
Speaker disclosure: Kazuhiko Nakagawa has acted as a consultant for AstraZeneca, Eli Lilly, Boehringer Ingelheim and Roche.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Lung Cancer
Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial
It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small […]
Raffaele Califano, ESMO 2019 – FLAURA study in NSCLC
Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust) joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125). Questions 1. Please describe the FLAURA trail and its reported results? (0:04) 2. Clinically, what impact do you think osimertinib will have over existing standard of care for patients […]
Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC
We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC. Questions 1. Could you tell us a little about the MYSTIC study and its major findings? (00:07) 2. What was […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!